Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C-Reference-Cited by-同舟云学术

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C

Published:1997-07 Issue:1 Volume:27 Page:56-62
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Saracco Giorgio,Borghesio Elisabetta,Mesina Pietro,Solinas Antonello,Spezia Claudia,Macor Franco,Gallo Vittorio,Chiandussi Livio,Donada Carlo,Donadon Valter,Spirito Fulvio,Mangia Alessandra,Andriulli Angelo,Verme Giorgio,Rizzetto Mario

Publisher

Elsevier BV

Subject

Hepatology

Reference35 articles.

1. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial;Davis;N Engl J Med,1989

2. Recombinant interferon alpha theraphy for chronic hepatitis C: a randomized double-blind, placebo-controlled trial;Di Bisceglie;N Engl J Med,1989

3. A randomized controlled trial of interferon alpha-2b as therapy for chronic non A, non B hepatitis;Saracco;J Hepatol,1990

4. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience;Weiland;J Hepatol,1990

5. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France;Marcellin;Hepatology,1991

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term Pegylated Interferon Monotherapy Following 72 Weeks of Pegylated Interferon and Ribavirin in Hepatitis C Virus Genotype-1-infected Slow Responders;Internal Medicine;2015

2. Safety and efficacy of interferon-beta therapy for hemodialysis patient with HCV;Nihon Toseki Igakkai Zasshi;2009

3. Incidence of Type 2 Diabetes Mellitus and Glucose Abnormalities in Patients With Chronic Hepatitis C Infection by Response to Treatment: Results of a Cohort Study;The American Journal of Gastroenterology;2008-10

4. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma;Annals of Oncology;2008-08

5. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection;Journal of Viral Hepatitis;2008-07-18